PXS Cancer Drug Ready to Commence Phase 2 Studies Q4 2020
Filed with ASX · · 3 pages · English
Earlier from Syntara
- Quarterly Shareholder Update - December 2019
- Pharmaxis Business Plan Update
- Quarterly Shareholder Update - September 2019
- FDA Provides Guidance on Bronchitol Approval Steps
- Pharmaxis Receives $6.2m R&D Tax Incentive
Later from Syntara
- Pharmaxis Quarterly Shareholder Update - March 2020
- Fourth Quarter Activity Report
- US$7 million Bronchitol Launch Milestone Brought Forward
- FDA Gives Green Light to Start Myelofibrosis Phase 2 Study
- Pharmaxis Awarded $1M Australian Government Grant
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara